sarpogrelate has been researched along with Albuminuria in 5 studies
sarpogrelate: structure given in first source
Albuminuria: The presence of albumin in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Forty patients who had diabetes with nephropathy and arteriosclerosis obliterans and had already been treated with angiotensin II receptor blocker (n = 40) were randomly assigned to sarpogrelate (300 mg/d; n = 20) or aspirin group (100 mg/d; n = 20)." | 9.13 | Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes. ( Ishizuka, T; Ito, S; Mori, T; Nako, K; Ogawa, S, 2008) |
| " We then investigated the effects of 24-month treatment with sarpogrelate hydrochloride, a 5-HT(A2) receptor antagonist, on urinary albumin level in 10 type 2 diabetics with microalbuminuria, compared with not treated control group." | 9.10 | Sarpogrelate hydrochloride, a serotonin2A receptor antagonist, reduces albuminuria in diabetic patients with early-stage diabetic nephropathy. ( Haraguchi, T; Higashi, K; Kobori, S; Koga, N; Minami, J; Takahashi, T; Yano, M, 2002) |
| "Forty patients who had diabetes with nephropathy and arteriosclerosis obliterans and had already been treated with angiotensin II receptor blocker (n = 40) were randomly assigned to sarpogrelate (300 mg/d; n = 20) or aspirin group (100 mg/d; n = 20)." | 5.13 | Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes. ( Ishizuka, T; Ito, S; Mori, T; Nako, K; Ogawa, S, 2008) |
| " We then investigated the effects of 24-month treatment with sarpogrelate hydrochloride, a 5-HT(A2) receptor antagonist, on urinary albumin level in 10 type 2 diabetics with microalbuminuria, compared with not treated control group." | 5.10 | Sarpogrelate hydrochloride, a serotonin2A receptor antagonist, reduces albuminuria in diabetic patients with early-stage diabetic nephropathy. ( Haraguchi, T; Higashi, K; Kobori, S; Koga, N; Minami, J; Takahashi, T; Yano, M, 2002) |
| " Treatment with sarpogrelate improved ROS/NO imbalance in glomeruli, suppressed platelet aggregation in glomeruli, reduced platelet-derived microparticles, increased serum adiponectin level and reduced the level of albuminuria, compared with non-treated diabetic rats." | 3.74 | Blockade of serotonin 2A receptor improves glomerular endothelial function in rats with streptozotocin-induced diabetic nephropathy. ( Arakawa, S; Fujimoto, S; Haruna, Y; Kashihara, N; Kobayashi, S; Komai, N; Namikoshi, T; Sasaki, T; Satoh, M; Tomita, N, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, ES | 1 |
| Lee, MY | 1 |
| Kwon, MH | 1 |
| Kim, HM | 1 |
| Kang, JS | 1 |
| Kim, YM | 1 |
| Lee, EY | 1 |
| Chung, CH | 1 |
| Takahashi, T | 1 |
| Yano, M | 1 |
| Minami, J | 1 |
| Haraguchi, T | 1 |
| Koga, N | 1 |
| Higashi, K | 1 |
| Kobori, S | 1 |
| Kobayashi, S | 1 |
| Satoh, M | 1 |
| Namikoshi, T | 1 |
| Haruna, Y | 1 |
| Fujimoto, S | 1 |
| Arakawa, S | 1 |
| Komai, N | 1 |
| Tomita, N | 1 |
| Sasaki, T | 1 |
| Kashihara, N | 1 |
| Ogawa, S | 1 |
| Mori, T | 1 |
| Nako, K | 1 |
| Ishizuka, T | 1 |
| Ito, S | 1 |
| Ishimura, E | 1 |
| Nishizawa, Y | 1 |
| Emoto, M | 1 |
| Shoji, T | 1 |
| Inaba, M | 1 |
| Kawagishi, T | 1 |
| Morii, H | 1 |
3 trials available for sarpogrelate and Albuminuria
| Article | Year |
|---|---|
Sarpogrelate hydrochloride, a serotonin2A receptor antagonist, reduces albuminuria in diabetic patients with early-stage diabetic nephropathy.
Topics: Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Follow-Up Studies; Glycated | 2002 |
Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Arteriosclerosis Obliterans; Aspirin; Ch | 2008 |
Therapeutic effect of sarpogrelate, a new 5-hydroxytryptamine receptor 2A antagonist, on diabetic nephropathy and neuropathy.
Topics: Adult; Aged; Albuminuria; Diabetic Nephropathies; Diabetic Neuropathies; Female; Follow-Up Studies; | 1997 |
2 other studies available for sarpogrelate and Albuminuria
| Article | Year |
|---|---|
Sarpogrelate hydrochloride ameliorates diabetic nephropathy associated with inhibition of macrophage activity and inflammatory reaction in db/db mice.
Topics: Adiponectin; Adipose Tissue; Albuminuria; Animals; Body Weight; Cell Movement; Diabetic Nephropathie | 2017 |
Blockade of serotonin 2A receptor improves glomerular endothelial function in rats with streptozotocin-induced diabetic nephropathy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adiponectin; Albuminuria; Animals; Blood Platelets; Deoxyguanosine; Dia | 2008 |